Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | APAF1 | O14727 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781820 | 0.82 | DAO (0.51) | KDM4EALDH1A1GAAPOLBHSD17B10 | |
| SCHEMBL19892669 | 0.79 | DAO (0.42) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL105569 | 0.77 | MAOB (0.48) | HTR2C | |
| Hydrochloric Acid SCHEMBL2209444 | 0.76 | HTR2C (0.48) | HTR2C | |
| Hydrochloric Acid SCHEMBL31318331 | 0.76 | HTR2C (0.48) | HTR2C | |
| SCHEMBL13792217 | 0.73 | SLC6A2 (0.40) | MAPT | |
| SCHEMBL29151429 | 0.73 | PARP1 (0.44) | KDM4EALDH1A1TSHRHTR2C | |
| SCHEMBL30747837 | 0.73 | PARP1 (0.44) | KDM4EALDH1A1TSHRHTR2C | |
| SCHEMBL2321324 | 0.73 | DAO (0.52) | — | |
| SCHEMBL14447539 | 0.73 | HTR6 (0.50) | ALDH1A1GAAPOLBSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-8829006-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2205590-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-06-04 | — | — | EP | disclosed |
| EP-2205590-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2205590-A1 | CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009050232-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050232-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059954-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | KDM4E 4621/4885ALDH1A1 1292/4885GAA 3559/4885 |
| US-20130029975-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | KDM4E 4621/4885ALDH1A1 1292/4885GAA 3559/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | KDM4E 4390/4885ALDH1A1 1405/4885GAA 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.